Company Overview

Mainz Biomed N.V. is a molecular diagnostics company focused on the early detection of cancer, with a primary emphasis on colorectal cancer. The company operates within the biotechnology and in‑vitro diagnostics industries, developing non‑invasive, DNA‑based screening tests intended to improve early diagnosis and patient outcomes. Its core products are designed to analyze stool or blood samples using molecular biomarkers associated with cancer and precancerous lesions.

The company’s principal commercial product is ColoAlert®, a stool‑based colorectal cancer screening test that combines molecular biomarker detection with immunochemical analysis. Mainz Biomed’s business model centers on the development, regulatory approval, and commercialization of proprietary diagnostic assays, targeting healthcare providers, laboratories, and population‑wide screening programs. The company traces its origins to Germany and later established a corporate presence in the Netherlands, ultimately becoming publicly listed in the United States through a business combination that enabled access to public capital markets.

Business Operations

Mainz Biomed conducts its operations through integrated research, development, clinical validation, and commercialization activities. Its primary operating focus is molecular diagnostics, with revenue generation expected to come from test sales, laboratory partnerships, and licensing or distribution agreements. The company’s operations include assay development, clinical studies, regulatory submissions, and market rollout, particularly in regions with established colorectal cancer screening frameworks.

Operationally, Mainz Biomed maintains development and laboratory activities in Europe, while pursuing commercial expansion in the United States. The company relies on a combination of internal research capabilities and external collaborations with clinical laboratories and research institutions. Its technology platform is centered on proprietary multiplex real‑time PCR assays designed to detect cancer‑associated DNA markers with high sensitivity.

Strategic Position & Investments

Strategically, Mainz Biomed is focused on expanding the clinical utility and regulatory reach of ColoAlert® while advancing next‑generation diagnostic candidates, including blood‑based screening tests. A key growth initiative involves pursuing regulatory approval and reimbursement pathways in the United States, where colorectal cancer screening represents a large and competitive market. The company has publicly disclosed plans to conduct U.S. clinical trials to support regulatory submissions.

In addition to organic development, Mainz Biomed has engaged in targeted acquisitions and collaborations to strengthen its technology base. A notable acquisition includes Genetix GmbH, which expanded the company’s access to molecular diagnostic expertise and laboratory infrastructure. The company has also signaled interest in applying its biomarker and PCR technologies to other cancer indications, although commercialization beyond colorectal cancer remains in development stages.

Geographic Footprint

Mainz Biomed’s corporate headquarters are located in Mainz, Germany, with its legal domicile in the Netherlands. The company maintains operational and research activities across Europe, leveraging established colorectal cancer screening programs in countries such as Germany to support clinical validation and early commercialization.

Internationally, Mainz Biomed is focused on expanding its footprint in North America, particularly the United States, which represents its largest target growth market. The company’s global strategy emphasizes partnerships, regulatory approvals, and market entry in regions with high screening adoption and reimbursement potential, rather than building extensive standalone infrastructure in every geography.

Leadership & Governance

Mainz Biomed is led by an executive team with experience in biotechnology, diagnostics, and capital markets. The leadership’s stated strategic vision centers on advancing early cancer detection through clinically validated, non‑invasive molecular diagnostics and scaling these solutions globally through partnerships and regulatory approvals.

Key executives include:

• Guido Baechler – Chief Executive Officer
• Ulrich Schlenk – Chief Financial Officer
• Dr. Moritz Heuser – Chief Operating Officer
• Dr. Andreas Selch – Chief Scientific Officer

The company is governed by a supervisory board structure consistent with European corporate governance standards, providing oversight of strategy, financial management, and long‑term value creation.